Prevalence of possible drug-drug interactions between antiretroviral agents in different age groups in a section of the private health care sector setting in South Africa

Journal of Clinical Pharmacy and Therapeutics

Volumn 33, Issue 4, 2008, Pages 393-400

  Katende Kyenda, N L ^c   Lubbe, M S ^a   Serfontein, J H P ^a   Truter, I ^b  

^a NORTH WEST UNIVERSITY   (South Africa)

^b NELSON MANDELA METROPOLITAN UNIVERSITY   (South Africa)

^c NONE   (Saudi Arabia)

Author keywords

Age groups; Antiretroviral agents; Drug drug interactions; Human immunodeficiency virus patients; Private health care

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DRUG USE; FEMALE; GROUPS BY AGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; PRESCRIPTION; PRIMARY HEALTH CARE; SOUTH AFRICA; AGE DISTRIBUTION; DRUG INTERACTION; FACTUAL DATABASE; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PRESCHOOL CHILD; PREVALENCE; RETROSPECTIVE STUDY; STATISTICS;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DRUG INTERACTIONS; DRUG UTILIZATION REVIEW; FEMALE; HIV INFECTIONS; HUMANS; INFANT; MALE; MIDDLE AGED; PREVALENCE; PRIVATE SECTOR; RETROSPECTIVE STUDIES; SOUTH AFRICA;

EID: 49849104125     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2008.00930.x     Document Type: Article

References (23)

1. Highleyman L (2005) Drug interactions and anti-HIV therapy. The body: the complete HIV / AIDS resource. Available at: http://www.thebody.com/ content/treat/art2579.html (accessed 2 August 2007).
2. Agins BD, Mojica-Rogers C (2003) Drug interactions associated with HAART. AIDS Read, 13, 433-450. Available at: http://www.medscape.com/viewarticle/ 461892-4 (accessed 29 July 2007).
3. Wood R (2006) Antiretroviral medicines (ARVs). Expert annexure. Available at: http://www.tac.org.za/ Document/DrugcomapaniesCC/Tau-V-GSK-woodaffidavit. doc (accessed 18 July 2007).
4. National Department of Health South Africa (2004) National antiretroviral treatment guidelines. Department of Health: Pretoria, South Africa. Available at: http://doh.gov.za/docs/factsheets/guidelines/ artguideline04-f.html (accessed 10 May 2008).
5. Crucio-Souza JM, Thomoson JC (2006) Prevalence of potential drug-drug interactions and its associated factors in a Brazilian teaching hospital. Journal of Pharmacy Pharmaceutical Sciences, 9, 427-433.
6. Juurlink DN, Mamdani M, Kopp A et al. (2003) Drug-drug interactions among elderly patients hospitalized for drug-toxicity. Journal of the American Medical Association, 289, 1652-1658.
7. Geppert U, Beindl W, Hawranek T et al. (2003) Drug interactions in clinical practice. A pilot project for quality assurance in prescribing. Hautarzt, 54, 53-57.
8. Bobb A, Gleason K, Husch M et al. (2004) The epidemiology of prescribing errors: the potential impact of computerised prescriber order entry. Archives of Internal Medicine, 164, 785-792.
9. Klarin I, Wimo A, Fastbom J (2005) The association of inappropriate drug use with hospitalization and mortality. Population-based study of the very old. Drugs and Aging, 22, 69-82.
10. SAS Institute (2005) Statistical analysis system (SAS 9.1) software version 9.1. Cary, NC: SAS Institute.
11. Tatro DS (2005) Drug interaction facts 2005. St. Louis, MO: Facts and Comparisons, 1-1699.
12. Synman JR (2007) Antimicrobials. In: Snyman JR, ed. Mims medical specialities, Vol.44. Pinegowrie: Johnic Mims, 251-306.
13. South African HIV & AIDS Statistics Summary (2006) The South African Department of Health Study, 2006. Available at: http://www.avert.org/ safricastats.htm (accessed 21 August 2007).
14. Statistics South Africa (2003) Census, 2001. Pretoria, South Africa: Statistics South Africa. Available at: http://www.statssa.gov.za/census01/html/ clnBrief/ CIB2003.pdf (accessed 27 March 2007).
15. United States Department of Health and Human Sciences (2004) A guide to primary care for people with HIV / AIDS, 2004 Edition. Available at: http:// www.ftp.hrsa.gov/hab/PCGchap5.pdf (accessed 6 December 2007).
16. Malaty LI, Kuper JJ (1999) Drug interactions of HIV protease inhibitors. Drug Safety, 20, 147-169.
17. Palella FJ Jr, Delaney KM, Moorman AC et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine, 338, 853-860.
18. Rhame FS, Rawlins SL, Petruschke RA et al. (2004) Pharmacokinetics of indinavir and ritonavir administered at 667 and 100 milligrams, respectively, every 12 hours compared with indinavir admininistered at 800 mg every 8 hours in human immunodeficiency virus-infected patients. Antimicrobial Agents Chemotherapy, 48, 4200-4208.
19. Saah AJ, Winchell GA, Nessly ML et al. (2001) Pharmacokinetic profile and tolerability of indinavirritonavir combinations in healthy volunteers. Antimicrobial Agents Chemotherapy, 45, 2710-2715.
20. Groot R, de Burger DM, Hartwig NG et al. (2005) Increased dose of lopinavir / ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children. Journal of Acquired Immune\Deficiency Syndrome, 39, 63-68.
21. Aarnoutse RE, Burger DM, Hugen PWH et al. (2000) A pharmacokinetic (PK) study to investigate the influence of efavirenz (EFV) on a BID indinavir (IDV) / ritonavir(RTV) regimen (800 / 100 mg) in healthy volunteers. Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, Toronto, ON: Abstract 423.
22. Moreno A, Casado JL, Marti-Belda P et al. (2001) Concomitant use of non-nucleoside reverse transcriptase inhibitors (NNRTIs) does not decrease the inhibitory quotient of dual ritonavir-indinavir-based therapy. Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, Chicago, IL: Abstract 1-1728.
23. Krikorian SA (2005) Drug-drug interactions and HIV therapy: what should pharmacist know? Journal of Pharmacy Practice, 18, 278-294.